BioVie Presents Phase 2 Bezisterim Data in Long COVID
BioVie said ADDRESS-LC trial data showed statistically significant improvements versus placebo in fatigue, post-exertional malaise and objective cognitive measures among Long COVID patients with higher baseline symptom burden.